share_log

4: Statement of changes in beneficial ownership of securities-Officer Tapolczay David

4: Statement of changes in beneficial ownership of securities-Officer Tapolczay David

4：持股變動聲明-高管 Tapolczay David
美股SEC公告 ·  11/21 05:33

牛牛AI助理已提取核心訊息

Conduit Pharmaceuticals Inc. (CDT.US) has reported a transaction involving its Chief Executive Officer, David Tapolczay. The transaction took place on November 18, 2024. However, the announcement did not disclose the number of shares transacted, the nature of the shares, the transaction price, or the total value of the shares. Additionally, the number of shares held by Tapolczay after the transaction was not provided. This information is typically significant for investors as it can indicate the confidence of company insiders in the firm's prospects.
Conduit Pharmaceuticals Inc. (CDT.US) has reported a transaction involving its Chief Executive Officer, David Tapolczay. The transaction took place on November 18, 2024. However, the announcement did not disclose the number of shares transacted, the nature of the shares, the transaction price, or the total value of the shares. Additionally, the number of shares held by Tapolczay after the transaction was not provided. This information is typically significant for investors as it can indicate the confidence of company insiders in the firm's prospects.
Conduit Pharmaceuticals Inc.（CDt.US）報告了一項涉及其首席執行官David Tapolczay的交易。這筆交易發生在2024年11月18日。然而，公告並未披露交易的股份數量、股票性質、交易價格或股份的總價值。此外，Tapolczay在交易後持有的股份數量也沒有提供。對投資者來說，這些信息通常很重要，因爲它可以表明公司內部人士對公司前景的信心。
Conduit Pharmaceuticals Inc.（CDt.US）報告了一項涉及其首席執行官David Tapolczay的交易。這筆交易發生在2024年11月18日。然而，公告並未披露交易的股份數量、股票性質、交易價格或股份的總價值。此外，Tapolczay在交易後持有的股份數量也沒有提供。對投資者來說，這些信息通常很重要，因爲它可以表明公司內部人士對公司前景的信心。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間